Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisition

By sjmartinez • June 12, 2023

Seaton KE, Huang Y, Karuna S, Heptinstall JR, Brackett C, Chiong K, Zhang L, Yates NL, Sampson M, Rudnicki E, Juraska M, deCamp AC, Edlefsen PT, Mullins JI, Williamson C, Rossenkhan R, Giorgi EE, Kenny A, Angier H, Randhawa A, Weiner JA, Rojas M, Sarzotti-Kelsoe M, Zhang L, Sawant S, Ackerman ME, McDermott AB, Mascola JR, Hural J, McElrath MJ, Andrew P, Hidalgo JA, Clark J, Laher F, Orrell C, Frank I, Gonzales P, Edupuganti S, Mgodi N, Corey L, Morris L, Montefiori D, Cohen MS, Gilbert PB, Tomaras GD. Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisition. EBioMedicine. 2023 Jun 8;93:104590. doi: 10.1016/j.ebiom.2023.104590. Epub ahead of print. PMID: 37300931.

Tags: Body weight-based dosing, Broadly neutralising antibodies, HIV, Infectious Diseases, prevention, Publications

The obstacle is the way: Finding a path to hepatitis C elimination

Lo Re V 3rd, Price JC, Schmitt S, Terrault N, Bhattacharya D, Arohnson A. The obstacle is the way: Finding a path to hepatitis C[...]

Severe Acute Respiratory Syndrome Coronavirus 2 Infection Alters Mediators of Lung Tissue Remodeling In Vitro and In Vivo

Wong M, Gain C, Sharma MB, Fotooh Abadi L, Hugo C, Vassilopoulos H, Daskou M, Fishbein GA, Kelesidis T. Severe Acute Respiratory Syndrome Coronavirus 2[...]

Safety, Efficacy, and Pharmacokinetics of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies BMS-986414 (C135-LS) and BMS-986413 (C144-LS) Administered Subcutaneously in Non-Hospitalized Persons with COVID-19 in a Phase 2 Trial

Corado KC, Chew KW, Giganti MJ, Mu Y, Fletcher CV, Currier JS, Daar ES, Wohl DA, Li JZ, Moser CB, Ritz J, Javan AC, Neytman[...]